144 related articles for article (PubMed ID: 29623014)
41. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
[TBL] [Abstract][Full Text] [Related]
42. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
[TBL] [Abstract][Full Text] [Related]
43. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
[TBL] [Abstract][Full Text] [Related]
44. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
45. PIK3CA as an oncogene in cervical cancer.
Ma YY; Wei SJ; Lin YC; Lung JC; Chang TC; Whang-Peng J; Liu JM; Yang DM; Yang WK; Shen CY
Oncogene; 2000 May; 19(23):2739-44. PubMed ID: 10851074
[TBL] [Abstract][Full Text] [Related]
46. Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.
Pfarr N; Allgäuer M; Steiger K; Weichert W; Schirmacher P; Noske A; Stenzinger A
Pathology; 2019 Jun; 51(4):362-368. PubMed ID: 31010589
[TBL] [Abstract][Full Text] [Related]
47. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
48. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K; Stokoe D; Taketani Y; McCormick F
Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209
[TBL] [Abstract][Full Text] [Related]
49. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.
Kadota M; Sato M; Duncan B; Ooshima A; Yang HH; Diaz-Meyer N; Gere S; Kageyama S; Fukuoka J; Nagata T; Tsukada K; Dunn BK; Wakefield LM; Lee MP
Cancer Res; 2009 Sep; 69(18):7357-65. PubMed ID: 19706770
[TBL] [Abstract][Full Text] [Related]
50. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
51. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
Front Oncol; 2020; 10():1023. PubMed ID: 32695676
[No Abstract] [Full Text] [Related]
52. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
53. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
54. Mutation of the
Stec R; Semeniuk-Wojtaś A; Charkiewicz R; Bodnar L; Korniluk J; Smoter M; Chyczewski L; Nikliński J; Szczylik C
Oncol Lett; 2015 Sep; 10(3):1423-1429. PubMed ID: 26622684
[TBL] [Abstract][Full Text] [Related]
55. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
Whyte DB; Holbeck SL
Biochem Biophys Res Commun; 2006 Feb; 340(2):469-75. PubMed ID: 16376301
[TBL] [Abstract][Full Text] [Related]
56. PIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma.
Firoozinia M; Zareian Jahromi M; Moghadamtousi SZ; Nikzad S; Abdul Kadir H
Int J Med Sci; 2014; 11(6):620-5. PubMed ID: 24782652
[TBL] [Abstract][Full Text] [Related]
57. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
Psyrri A; Papageorgiou S; Liakata E; Scorilas A; Rontogianni D; Kontos CK; Argyriou P; Pectasides D; Harhalakis N; Pappa V; Kolialexi A; Economopoulou C; Kontsioti F; Maratou E; Dimitriadis G; Economopoulou P; Economopoulos T
Clin Cancer Res; 2009 Sep; 15(18):5724-32. PubMed ID: 19723646
[TBL] [Abstract][Full Text] [Related]
58. PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma.
Zhang L; Shi L; Zhao X; Wang Y; Yue W
Onco Targets Ther; 2013; 6():497-502. PubMed ID: 23674897
[TBL] [Abstract][Full Text] [Related]
59. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
60. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
